跳转至内容
Merck
CN

P1793

Sigma-Aldrich

匹莫齐特

≥98% (TLC), powder, D₂ dopamine receptor antagonist

别名:

1-[1-[4,4-双（4-氟苯基）丁基]-4-哌啶基]-1,3-二氢-2H-苯并咪唑-2-酮

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C28H29F2N3O
化学文摘社编号:
2062-78-4
分子量:
461.55
EC 号:
218-171-7
MDL编号:
MFCD00055081
UNSPSC代码:
12352200
PubChem化学物质编号:
24277923
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

匹莫齐特,

表单

powder

质量水平

200

溶解性

DMSO: 18 mg/mL(lit.)
chloroform: 5 mg/mL
H2O: insoluble(lit.)

创始人

Teva

储存温度

2-8°C

SMILES字符串

Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5

InChI

1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)

InChI key

YVUQSNJEYSNKRX-UHFFFAOYSA-N

基因信息

human ... ABCB1(5243), CACNA1G(8913), CYP3A4(1576), DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816), HTR2A(3356), HTR7(3363), KCNH1(3756), KCNH2(3757), OPRD1(4985)
mouse ... Abcb1a(18671), Abcb1b(18669)
rat ... Scnn1g(24768)

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

D 2 多巴胺受体拮抗剂；与克隆的 5-HT 7 受体高亲和力结合；Ca 2 + 通道拮抗剂；抗精神病药

特点和优势

该化合物在受体分类和信号转导手册的环核苷酸门控（CNG）和超极化激活的环核苷酸门控（HCN）通道页面上有详细描述。想要浏览手册的其他页面， 请单击此处。
该化合物是环核苷酸研究的特色产品。 点击此处 ，发现更多特色环核苷酸产品。。在 sigma.com/discover-bsm了解更多关于其他研究领域的生物活性小分子。
该化合物由 Teva 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表，请点击此处。

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000463569
0000463567
0000463569
0000463567
0000428602

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Holger H H Erb et al.
PloS one, 15(8), e0237248-e0237248 (2020-08-14)
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour progression and
Junjun Chen et al.
Chemistry & biology, 18(11), 1390-1400 (2011-11-29)
Ubiquitin-specific proteases (USPs) have in recent years emerged as a promising therapeutic target class. We identified selective small-molecule inhibitors against a deubiquitinase complex, the human USP1/UAF1, through quantitative high throughput screening (qHTS) of a collection of bioactive molecules. The top
Erik A Nelson et al.
Blood, 117(12), 3421-3429 (2011-01-15)
The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous leukemia (CML). In CML, the BCR/ABL fusion kinase causes the constitutive activation of STAT5, thereby driving the expression of genes promoting survival. BCR/ABL kinase inhibitors have
L A Opler et al.
The Journal of clinical psychiatry, 52(5), 221-233 (1991-05-01)
Pimozide, a diphenylbutylpiperidine neuroleptic which is FDA-approved as a backup treatment for Gilles de la Tourette's syndrome, has been used abroad for many years as a treatment of schizophrenia and has been recently reported to be particularly effective in treating
Tamara Pringsheim et al.
The Cochrane database of systematic reviews, (2)(2), CD006996-CD006996 (2009-04-17)
Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new
查看所有相关文献

商品

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持